Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension for use in stress echocardiography.

14 Dec 2010

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Medicare patients with a host of physical problems are getting better care at the University of Michigan Health System, and U-M staff have saved more than $15 million on the cost of that care over four years.

13 Dec 2010

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

10 Dec 2010

HeartWare prices public offering of convertible senior notes due 2017

HeartWare International, Inc. announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") yesterday.

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.

9 Dec 2010

HeartWare announces $100 million convertible senior notes offering

HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.

9 Dec 2010

Poorly educated people more likely to be admitted in hospital with chronic heart failure

Results from a large European study suggest that poorly educated people are more likely to be admitted to hospital with chronic heart failure than the better educated, even after differences in lifestyle have been taken into account. The study is published online today (Thursday 9 December) in the European Heart Journal.

9 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

Detection of blood biomarker cTnT associated with structural heart disease

With the use of a highly sensitive test, detection of the blood biomarker cardiac troponin T, a cardiac-specific protein, is associated with structural heart disease and an increased risk of all-cause death, according to a study in the December 8 issue of JAMA.

8 Dec 2010

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

For most people, overeating and drinking at holiday parties will just result in weight gain. However, for millions of others who do not know they have type 2 diabetes, it could mean something much more serious.

8 Dec 2010

Study examines impact of poor care coordination on quality, cost of care in America

Many Americans seek medical treatment from a variety of care providers and often must play the role of informing each doctor what the others are recommending or prescribing. This fragmented experience of poorly coordinated care is due in part to a lack of consistent systems and processes in place to coordinate care across providers and facilities.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

Company reaches $28 million settlement for Medicare program

The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."

7 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

MU researcher hopes to protect cardiac muscles for children with DMD

Children with Duchenne muscular dystrophy face a future of rapidly weakening muscles, which usually leads to death by respiratory or cardiac failure before their 30th birthday. While researchers are hopeful that gene therapy could eventually evolve into an effective treatment, few have targeted the heart of the problem as much as Dongsheng Duan, PhD.

7 Dec 2010

Heart Failure News and Research

Further Reading

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

HeartWare prices public offering of convertible senior notes due 2017

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

HeartWare announces $100 million convertible senior notes offering

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

Poorly educated people more likely to be admitted in hospital with chronic heart failure

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Detection of blood biomarker cTnT associated with structural heart disease

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

Study examines impact of poor care coordination on quality, cost of care in America

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Company reaches $28 million settlement for Medicare program

New sensitive blood test could determine unrecognized heart disease

MU researcher hopes to protect cardiac muscles for children with DMD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News